Physician profile
Christopher P Mccarty
NPI 1912916099
$12,819.42
in general payments reported to CMS, 2019-2025
42 companies · $1,856 in 2025
The $1,856 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,209 · 2020: $1,281 · 2021: $1,844 · 2022: $1,083 · 2023: $1,301 · 2024: $1,246 · 2025: $1,856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669 · Travel and Lodging: $734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.26 |
| Travel and Lodging | $733.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,554.27 | 2019-2020 | |
| Medtronic, INC. | $1,696.04 | 2021-2025 | Corevalve Evolut R, Symplicity G3, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $1,058.35 | 2019-2025 | Aveir, Jot Dx, Assurity |
| Boston Scientific Corporation | $912.88 | 2019-2025 | Avvigo Guidance System, Opticross, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $893.23 | 2019-2024 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $840.58 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $623.20 | 2019-2024 | Farxiga |
| Amgen INC. | $607.16 | 2019-2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $515.32 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.88 | 2019-2024 | Jardiance |
| Pfizer INC. | $383.18 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $311.40 | 2019-2021 | |
| Abiomed | $277.38 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $258.84 | 2021-2024 | Verquvo |
| Shockwave Medical, INC | $147.12 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Mccarty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.